Dermatology

>

Latest News

Reaction: FDA approves roflumilast foam 0.3% for scalp, body psoriasis
Reaction: FDA approves roflumilast foam 0.3% for scalp, body psoriasis

May 28th 2025

Review some of the reactions from experts about the recent FDA approval of roflumilast foam 0.3% to treat scalp and body psoriasis in patients aged 12 years or older.

Weeky review: COVID-19 vaccine approved, framework laid out, and more
Weeky review: COVID-19 vaccine approved, framework laid out, and more

May 26th 2025

FDA approves roflumilast foam 0.3% for scalp, body psoriasis in adolescents, adults | Image credit: Contemporary Pediatrics
FDA approves roflumilast foam 0.3% for scalp, body psoriasis

May 22nd 2025

FDA approves pz-cel for recessive dystrophic epidermolysis bullosa | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves pz-cel for recessive dystrophic epidermolysis bullosa

April 29th 2025

FDA approves dupilumab for chronic spontaneous urticaria in ages 12 and up | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves dupilumab for chronic spontaneous urticaria in ages 12 and up

April 18th 2025

Latest CME Events & Activities

A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology

View More

Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age

View More

Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

View More

<1
...
3940414243
© 2025 MJH Life Sciences

All rights reserved.